IBRX | ImmunityBio, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.96 - 5.31
52 Week Range	2.6650 - 10.53
Beta	-0.15
Implied Volatility	129.28%
IV Rank	19.42%
Day's Volume	3,939,228
Average Volume	4,692,112
Shares Outstanding	696,533,000
Market Cap	3,621,971,600
Sector	Healthcare
Industry	Biotechnology
IPO Date	2015-07-28

Valuation
Profitability
Growth
Health
P/E Ratio	-5.42
Forward P/E Ratio	-11.80
EPS	-0.96
1YR Price Target	7.50
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	622
Country	USA
Website	IBRX

ImmunityBio Inc is a late-clinical-stage immunotherapy company developing next-generation therapies that drive immunogenic mechanisms for defeating cancers and infectious diseases. The company's immunotherapy platform activates both the innate (natural killer cell and macrophage) and adaptive (T cell) immune systems to create long-term immunological memory.

IBRX's peers: ALDX, ARDX, BLRX, CTXR, EYEN, LXRX, MCRB, EFTR, PLX, PDSB, LIFE, ELEV, CVAC, RETA, KRYS, VIR, PPCB, VKTX, TGTX, XFOR, MDGL, ORMP, XERS

*Chart delayed

Analyzing fundamentals for IBRX we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is frighteningly weak. For more detailed analysis please see IBRX Fundamentals page.

Watching at IBRX technicals we can see that long-term trend is bullish, the same as bullish middle-term trend, as well as bullish short-term trend. More technicals details can be found on IBRX Technicals page.